Oral cladribine will not be marketed for multiple sclerosis and the drug will be pulled in countries where it has already received approval, according to an announcement from manufacturer Merck KGaA.
Latest News
Image broadcasting: teleconferencing useful in schizophrenia
June 8, 2011UPDATE ON SCHIZOPHRENIA – The advent of teleconferencing technology has enabled telepsychiatry programs to improve access to mental health services, notably in countries such as Canada and Australia (Doze et al. J Telemed Telecare 1999; 5: 38-46). But is this approach appropriate in managing patients with psychotic disorders?
Metabolic effects of second-generation antipsychotics: meta-analysis
June 8, 2011UPDATE ON SCHIZOPHRENIA – Some second-generation antipsychotic medications are associated with substantially more metabolic side effects than other SGAs, according to a Cochrane analysis of 48 studies of schizophrenia (Rummel-Kluge et al. Schizophr Res 2010; 123: 225-233).
Pilot study of adjunctive L-lysine in schizophrenia
June 8, 2011UPDATE ON SCHIZOPHRENIA – Recent studies have suggested that dysfunctional nitric oxide (NO) signalling in the prefrontal cortex is involved in schizophrenia (Fejgin et al. Neuropsychopharmacology 2008; 33: 1874-1883; free full text at www.nature.com/npp/journal/v33/n8/full/1301587a.html). For example, in the phenylcyclidine model of schizophrenia, PCP-induced behavioural effects appear to be due in part to an increase in NO activity (Klamer et al. Eur Neuropsychopharmacol 2005; 15: 587-590; Johansson et al. Psychopharmacology (Berl); 1997; 131: 167-173).